NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04146363,Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1),https://clinicaltrials.gov/study/NCT04146363,,COMPLETED,"This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.",YES,Atopic Dermatitis,BIOLOGICAL: Lebrikizumab|OTHER: Placebo,"Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16, The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification., Baseline to Week 16|Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16, The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe).

The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score., Baseline to Week 16","Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 2, The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification., Baseline to Week 2|Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 4, The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification., Baseline to Week 4|Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 in Adults, The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification., Baseline to Week 16|Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) From Baseline to Week 16, The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe).

The EASI-90 responder is defined as a participant who achieves a ≥ 90% improvement from baseline in the EASI score., Baseline to Week 16|Percent Change in Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16, Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating ""No itch"" and 10 indicating ""Worst itch imaginable."" Least Squares (LS) Mean was calculated using analysis of covariance (ANCOVA) model with treatment and randomization strata (region, disease severity, age) as fixed factors and baseline value as covariate., Baseline, Week 16|Percentage of Participants With a Pruritus NRS Score of ≥4-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16, Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating ""No itch"" and 10 indicating ""Worst itch imaginable."", Baseline to Week 16|Percentage of Participants With a Pruritus NRS Score of ≥5-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16, Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating ""No itch"" and 10 indicating ""Worst itch imaginable."", Baseline to Week 16|Percent Change in EASI Score From Baseline to Week 16, The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe).

LS Mean was calculated using ANCOVA model with treatment, stratification factors of geographic region, age group, baseline IGA score (IGA 3 versus 4) as fixed factors baseline value as covariate., Baseline, Week 16|Change From Baseline in Percent Body Surface Area (BSA) at Week 16, The BSA affected by AD will be assessed for 4 separate body regions: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. BSA was calculated using the participant's palm using the 1% rule, 1 palm was equivalent to 1% with estimates of the number of palms it takes to cover the affected AD area. Maximum number of palms were 10 palms for head and neck (10%), 20 palms for upper extremities (20%), 30 palms for trunk, including axilla and groin (30%), 40 palms for lower extremities, including buttocks (40%). Percent of BSA for a body region was calculated as = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA of all 4 body regions ranges from 0% to 100 % with higher values representing greater severity of AD., Baseline, Week 16|Percentage of Participants Achieving EASI-90 From Baseline to Week 4, The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe).

The EASI-90 responder is defined as a participant who achieves a ≥ 90% improvement from baseline in the EASI score., Baseline to Week 4|Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16, The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include ""Not at all,"" ""A little,"" ""A lot,"" and ""Very much,"" with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of ""Not relevant"" which is scored as ""0"". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life.

LS Mean was calculated using the ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors., Baseline, Week 16|Percentage of Participants Achieving ≥4 Point Improvement in DLQI From Baseline to Week 16, The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include ""Not at all,"" ""A little,"" ""A lot,"" and ""Very much,"" with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of ""Not relevant"" which is scored as ""0"". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life., Baseline to Week 16|Percentage of Participants With a DLQI Total Score of ≥4-point at Baseline Achieving ≥4-point Improvement in DLQI From Baseline to Week 16, The DLQI is a 10-item, validated questionnaire used to assess the impact of skin disease on the quality of life of an affected person. The 10 questions cover the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment, over the previous week. Response categories include ""Not at all,"" ""A little,"" ""A lot,"" and ""Very much,"" with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of ""Not relevant"" which is scored as ""0"". Questions are scored from 0 to 3, giving a possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life., Baseline to Week 16|Percent Change in Sleep-loss Score From Baseline to Week 16, Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary. LS Mean was calculated using ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors., Baseline, Week 16|Change From Baseline in Sleep-loss Score at Week 16, Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary. LS Mean was calculated using ANCOVA model with treatment, baseline value, and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors., Baseline, Week 16|Percentage of Participants With a Sleep-loss Score ≥2 Points at Baseline Who Achieve a ≥2 Points Reduction From Baseline at Week 16, Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicated a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary., Baseline to Week 16|Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1, Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating ""No itch"" and 10 indicating ""Worst itch imaginable."", Baseline to Week 1|Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2, Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating ""No itch"" and 10 indicating ""Worst itch imaginable."", Baseline to Week 2|Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4, Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating ""No itch"" and 10 indicating ""Worst itch imaginable."", Baseline to Week 4|Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1, Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating ""No itch"" and 10 indicating ""Worst itch imaginable."", Baseline to Week 1|Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2, Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating ""No itch"" and 10 indicating ""Worst itch imaginable."", Baseline to Week 2|Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4, Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating ""No itch"" and 10 indicating ""Worst itch imaginable."", Baseline to Week 4|Percent Change in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16, The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease.

LS Mean was calculated using the ANCOVA model with treatment group and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate., Baseline, Week 16|Pharmacokinetics (PK): Average Serum Concentration of Lebrikizumab at Week 52, PK: Average serum concentration of lebrikizumab at the Week 52 trough timepoint. Serum concentration is a combined measure obtained from Baseline, Week 4, Week 16, Week 32, Week 52 and average measure was reported at week 52., Predose: Baseline, Week 4, Week 16, Week 32, Week 52|Percentage of Participants From Those Re-randomized Having Achieved EASI-75 at Week 16 Who Continued to Exhibit EASI-75 at Week 52 (EASI-75 Calculated Relative to Baseline EASI Score), The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe).

The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score., Baseline to Week 52|Percentage of Participants From Those Re-randomized Having Achieved IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 16 Who Continue to Exhibit and IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 52, The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification., Baseline to Week 52|Percentage of Participants From Those With a Pruritus NRS of ≥4-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52, Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating ""No itch"" and 10 indicating ""Worst itch imaginable."", Baseline to Week 52|Percentage of Participants From Those With a Pruritus NRS of ≥5-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52, Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating ""No itch"" and 10 indicating ""Worst itch imaginable."", Baseline to Week 52|Percent Change in SCORAD (Having Achieved EASI-75 at Week 16) From Baseline at Week 52, The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. LS mean was calculated using ANCOVA model with treatment group, baseline value, and stratification factors geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate., Baseline, Week 52|Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) at Week 16 - Health State Index, The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state.

LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate., Baseline, Week 16|Change From Baseline in EQ-5D-5L at Week 16 - Visual Analog Scale (VAS), The EQ-5D-5L is a 2-part measurement. The second part is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate., Baseline, Week 16|Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16, POEM is a 7-item, validated, questionnaire used by the participant to assess disease symptoms over the last week. The participant is asked to respond to 7 questions on skin dryness, itching, flaking, cracking, sleep loss, bleeding and weeping. All 7 answers carry equal weight with a total possible score from 0 to 28 (answers scored as: No days=0; 1# 2 days = 1; 3-4 days = 2; 5#6 days = 3; everyday = 4). A high score is indicative of a poor quality of life. POEM responses will be captured using an electronic diary and transferred into the clinical database. LS Mean was calculated using MMRM model using treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit as covariates, geographic region, age group, baseline IGA (3 versus 4) score as fixed., Baseline, Week 16|Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety at Week 16 - Adolescents, PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate., Baseline, Week 16|Change From Baseline in PROMIS Depression at Week 16 - Adolescents, PROMIS® is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Participants ≤17 years will complete pediatric versions for the duration of the study. PROMIS depression has 8 questions on Emotion Distress-Depression (or Pediatric Depressive Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater depression. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate., Baseline, Week 16|Change From Baseline in PROMIS Anxiety at Week 16 - Adults, PROMIS is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. The PROMIS measures will be completed by the participant in the study clinic. PROMIS anxiety has 8 questions on Emotion Distress-Anxiety (or Pediatric Anxiety Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater anxiety. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate., Baseline, Week 16|Change From Baseline in PROMIS Depression at Week 16 - Adults, PROMIS is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. The PROMIS measures will be completed by the participant in the study clinic. PROMIS depression has 8 questions on Emotion Distress-Depression (or Pediatric Depressive Symptom). Each question has 5 response options with values from 1 to 5. Total raw scores were converted to T-Scores (mean = 50 and a standard deviation = 10) with higher scores representing greater depression. LS Mean was calculated using the ANCOVA model with treatment and stratification factors of geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate., Baseline, Week 16|Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score at Week 16 in Participants Who Have Self-Reported Comorbid Asthma, The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/ limitation) scale. The ACQ-5 score is the average of the individual item scores and ranges from 0 (totally controlled) to 6 (severely uncontrolled). Higher scores indicate lower asthma control.

LS Mean was calculated using ANCOVA with treatment, geographic region, age group, baseline IGA (3 versus 4) score as fixed factors and baseline value as covariate., Baseline, Week 16|Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16 - Adolescents, The CDLQI questionnaire is designed for use in children (4 to 16 years of age). It consists of 10 items that are grouped into 6 domains: symptoms \& feelings, leisure, school or holidays, personal relationships, sleep, \& treatment. The scoring of each question is: Very much =3; Quite a lot = 2; Only a little = 1; Not at all = 0. CDLQI total score is calculated by summing all 10 items responses and has a range of 0 to 30 (higher scores are indicative of greater impairment).

LS Mean was calculated using MMRM model which includes treatment, baseline value, visit, the interaction of the baseline value-by-visit as covariates, the interaction of treatment by-visit, geographic region, age group, and baseline IGA (3 versus 4) score as fixed factors., Baseline, Week 16",,Eli Lilly and Company,"Dermira, Inc.",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,424,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",17801|2019-002932-10|J2T-DM-KGAB|DRM06-AD04,2019-09-24,2021-06-21,2022-05-03,2019-10-31,2022-06-20,2022-11-30,"Johnson Dermatology, Fort Smith, Arkansas, 72916, United States|Wallace Medical Group, Inc., Beverly Hills, California, 90211, United States|California Dermatology & Clinical Research Institute, Encinitas, California, 92024, United States|Belle Aimee Skincare Clinic, Fountain Valley, California, 92708, United States|Dermatology Research Associates, Los Angeles, California, 90045, United States|ACRC Studies, San Diego, California, 92119, United States|Central Connecticut Dermatology, Cromwell, Connecticut, 06416, United States|St. Francis Medical Institute, Clearwater, Florida, 33765, United States|Community Research Foundation Inc, Miami, Florida, 33145, United States|ForCare Clinical Research, Tampa, Florida, 33613-1244, United States|IACT Health - VHC, Columbus, Georgia, 31903, United States|The Indiana Clinical Trials Center, Plainfield, Indiana, 46168, United States|Skin Sciences, PLLC, Louisville, Kentucky, 40217, United States|Beacon Clinical Research, LLC, Quincy, Massachusetts, 02169, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|St Joseph Dermatology and Vein Clinic, Saint Joseph, Michigan, 49085, United States|MediSearch Clinical Trials, Saint Joseph, Missouri, 64506, United States|JDR Dermatology Research, Las Vegas, Nevada, 89148, United States|ALLCUTIS Research, Portsmouth, New Hampshire, 03801, United States|Icahn Sch of Med at Mt. Sinai, New York, New York, 10029, United States|Sadick Research Group, New York, New York, 10075, United States|Wake Research Associates, Raleigh, North Carolina, 27612, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, 73112, United States|Vital Prospects Clinical Research Institute, P.C., Tulsa, Oklahoma, 74136, United States|Clinical Research Institute, Medford, Oregon, 97504, United States|Oregon Medical Research Center, Portland, Oregon, 97223, United States|Clinical Partners, LLC, Johnston, Rhode Island, 02919, United States|Bellaire Dermatology, Bellaire, Texas, 77401, United States|Progressive Clinical Research, San Antonio, Texas, 78213, United States|Premier Clinical Research, Spokane, Washington, 99202, United States|The St. George Hospital, Kogarah, New South Wales, 2217, Australia|Holdsworth House Medical Practice, Sydney, New South Wales, 2010, Australia|Skin & Cancer Foundation Australia, Westmead, New South Wales, 2145, Australia|The Skin Centre, Benowa, Queensland, 4217, Australia|Veracity Clinical Research Pty Ltd, Woolloongabba, Queensland, 4102, Australia|Eastern Clinical Research Unit, Box Hill, Victoria, 3128, Australia|Emeritus Research, Camberwell, Victoria, 3124, Australia|Skin Health Institute Inc., Carlton, Victoria, 3053, Australia|Sinclair Dermatology, East Melbourne, Victoria, 3002, Australia|Fremantle Dermatology, Fremantle, Western Australia, 6160, Australia|Burswood Dermatology, Victoria Park, Western Australia, 06100, Australia|CARe Clinic, Red Deer, Alberta, T4P1K4, Canada|CCA Medical Research, Ajax, Ontario, L1S7K8, Canada|Skin Health, Cobourg, Ontario, K9A 0Z4, Canada|Dermatology and Dermatologic Surgery, Ottawa, Ontario, K2G6E2, Canada|The Centre for Dermatology, Richmond Hill, Ontario, L4B 1A5, Canada|Kliiniliste uuringute Keskus OU, Tartu, 50160, Estonia|Hopital Saint-Louis, Paris, Cedex 10, 75475, France|CHU de Bordeaux Hopital Saint Andre, Bordeaux Cedex, 33075, France|CHU DIJON - Hopital le Bocage, Dijon Cedex, 21079, France|Cabinet Médical, Martigues, 13500, France|Hopital Larrey, Toulouse cedex 9, 31059, France|Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, 15355, Korea, Republic of|Pusan National University Hospital, Pusan, Korea, 49241, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, 04763, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, 44033, Korea, Republic of|Ajou University Hospital, Suwon-si, Kyung Gi-Do, Korea, 16499, Korea, Republic of|Soon Chun Hyang University Seoul Hospital, Seoul, Yongsan-gu, 04401, Korea, Republic of|Incheon St. Mary's Hospital, Incheon, 21431, Korea, Republic of|Severance Hospital, Seoul, 03722, Korea, Republic of|Konkuk University Medical Center, Seoul, 05030, Korea, Republic of|Chungang University Hospital, Seoul, 06973, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, 07441, Korea, Republic of|Clinic of Dermatology and STD, Riga, LV-1001, Latvia|Health Center 4, Affiliate Diagnostic Center, Riga, LV-1003, Latvia|Health and Aesthetics LTD, Riga, LV-1009, Latvia|Latvian Dermatology Institute, Riga, LV-1011, Latvia|Smite Aija - Practice in Dermatology Venereology, Talsi, LV-3201, Latvia|JSC ""CD8 Alergology Clinic"", Kaunas, LT-44192, Lithuania|Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas, LT-50161, Lithuania|Jsc Renmeda, Vilnius, LT-07195, Lithuania|JSC ""Center for Diagnosis and Treatment of Allergic Diseases"", Vilnius, LT-08109, Lithuania|Children's Hospital, Affiliate of Vilnius University Hospital Santaros klinikos, Vilnius, LT-08406, Lithuania|Inlita (Santaros CTC), Vilnius, LT-08406, Lithuania|Vilnius University Hospital Santaros klinikos, Vilnius, LT-08441, Lithuania|Alergo-Med Specjalistyczna Przychodnia Lekarska Sp Z O.O., Tarnow, Malopolska, 33100, Poland|Diamond Clinic, Krakow, Malopolskie, 31-559, Poland|Centralny Szpital Kliniczny MSWiA, Warszawa, Mazowieckie, 02-507, Poland|Centrum Medyczne Angelius Provita, Katowice, Slaskie, 40-611, Poland|Twoja Przychodnia - Szczecinskie Centrum Medyczne, Szczecin, West Pomeranian, 71-434, Poland|Zespol Naukowo - Leczniczy ""Iwolang"" Sp. z o.o., Iwonicz Zdroj, Wojewodztwo Podkarpackie, 38-440, Poland|GynCentrum Sp z o.o., Katowice, 40-851, Poland|Specjalistyczny Osrodek Alergologiczno-Internistyczny ALL-ME, Krakow, 31-023, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1, Lublin, 20-081, Poland|Centrum Alergologii Teresa Hofman, Poznan, 60-214, Poland|Clinical Research Group Sp. z o.o., Warszawa, 01-142, Poland|CityClinic Przychodnia Lekarsko-Psychologiczna, Wroclaw, 50-566, Poland|Sant Joan de Deu Serveis En Salut Mental, SANT BOI DE Llobrega, Barcelona, 08830, Spain|Hospital De Basurto, Bilbao, Vizcaya, 48013, Spain|Hospital General Universitario Alicante, Alicante, 03010, Spain|Hospital Germans Trias i Pujol, Badalona, 08916, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain|Hospital Infanta Leonor, Madrid, 28031, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/63/NCT04146363/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/63/NCT04146363/SAP_001.pdf"
